



Q2 2023 Financial Results

August 10, 2023





Cautionary Statement Regarding Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, which may include GAAP and non-GAAP financial measures, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. In particular, this presentation includes management's revenue outlook for 2023 as of August 10, 2023, which outlook is based on current estimates as of today's date. Estimating financial performance accurately for future periods is difficult as it involves assumptions and internal estimates that may prove to be incorrect and is based on plans and circumstances that may change. There is therefore a significant risk that actual results could differ materially from the outlook we have provided in this presentation, and we have no obligation to update such outlook. Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control and are not guarantees of future results, such as statements about future financial and operating results, company strategy and intended product offerings and market positioning. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with Forian's ability to execute on its strategy and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Forian's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the United States Securities and Exchange Commission ("SEC") on March 30, 2023, and elsewhere in Forian's filings and reports with the SEC. Forward-looking statements contained in this presentation are made as of the date hereof, and we undertake no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.



Revenue and Adjusted EBITDA



	QTR Ended June 30, (in 000's)			YTD June 30, (in 000's)		
	2023	2022	Change %	2023	2022	Change %
	Unaudited	Unaudited		Unaudited	Unaudited	
Total revenue	\$ 4,894	\$ 3,603	36%	\$ 9,764	\$ 7,138	37%
Loss from continuing operations, net of tax	\$ (1,090)	\$ (4,008)	73%	\$ (3,876)	\$ (14,326)	73%
(Loss) income from discontinued operations, net of tax	\$ (32)	\$ (1,425)	98%	\$ 8,715	\$ (2,962)	394%
Net (Loss) income	\$ (1,123)	\$ (5,434)	79%	\$ 5,376	\$ (17,288)	131%
Adjusted EBITDA	\$ 67	\$ (2,538)	103%	\$ (204)	\$ (5,233)	96%

- Organic revenue growth, 36% over the same quarter last year
- Continued improvement in Adjusted EBITDA

Adjusted EBITDA is a non-U.S. GAAP measure. See *Appendix* for further information, including a reconciliation of Adjusted EBITDA to Net Loss.





Healthcare Information Revenue Trend



36% Q2 2023 revenue growth over same quarter last year
37% Q2 2023 revenue growth over same period YTD last year





Costs and Expenses



Focused business model drives cost reductions:

- 15% decrease in Q2 2023 Costs and Expenses
- 36% decrease in YTD Q2 2023 Costs and Expenses

Adjusted EBITDA – continuing operations



Continued improvement in Adjusted EBITDA driven by revenue growth and cost management

Adjusted EBITDA is a non-U.S. GAAP measure. See **Appendix** for further information, including a reconciliation of Adjusted EBITDA to Net Loss.




Full Year 2023 Outlook

Expect 2023 Healthcare Information Revenue growth of 25% to 37% resulting in revenue in the range of \$20.5 to \$22.5 million

Continued Improvement in Adjusted EBITDA, with a positive Adjusted EBITDA contribution in the second half of 2023

The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See slide 2.



Adjusted EBITDA is a non-U.S. GAAP measure. See **Appendix** for further information, including a reconciliation of Adjusted EBITDA to Net Loss.



Summary Balance Sheet Data \$000's

	<u>June 30, 2023</u>
Cash and equivalents	\$41,247
Proceeds receivable – sale of discontinued operations	\$ 6,502
Net working capital	\$46,036
Convertible note and accrued interest (due 9/2025)	\$25,526
Shares outstanding	32,452

Q&A

Appendix



Reconciliation of U.S. GAAP to Non-GAAP Financial Measures

This presentation includes a non-GAAP measure, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-U.S. GAAP financial measure provided herein is earnings before interest, taxes, non-cash and other items (“**Adjusted EBITDA**”), which should be viewed as supplemental to, and not as an alternative for, net income or loss calculated in accordance with U.S. GAAP (referred to below as “**Net loss**”).

Adjusted EBITDA is used by our management as an additional measure of our Company’s performance for purposes of business decision-making, including developing budgets, managing expenditures and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our Company’s financial results that may not be shown solely by period-to-period comparisons of net income. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our Company’s performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those items.

We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of Net loss to Adjusted EBITDA, helps investors make comparisons between our Company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is not intended as a substitute for comparisons based on Net loss. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding U.S. GAAP measures provided by each company under applicable SEC rules.

Non-U.S. GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP. We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure to evaluate our business and to view our non-GAAP financial measures in conjunction with the most directly comparable U.S. GAAP financial measures.

Non-U.S. GAAP Reconciliations

Reported Net Income to Adjusted EBITDA

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2023	2022	2023	2022
Total revenues	\$ 4,893,542	\$ 3,602,913	\$ 9,763,929	\$ 7,137,774
Net loss from continuing operations	\$ (1,090,400)	\$ (4,008,132)	\$ (3,339,199)	\$ (14,325,832)
Depreciation and amortization	15,257	16,334	53,687	31,683
Stock based compensation expense	1,540,342	1,374,194	3,368,575	8,988,172
Change in fair value of warrant liability	(8,053)	(114,776)	(2,494)	(334,616)
Interest and investment income (expense)	(637,032)	(18,916)	(1,019,954)	(22,711)
Interest expense	210,758	208,648	419,214	419,981
Severance expense	-	-	250,000	-
Income tax expense	36,187	5,000	66,096	10,000
Adjusted EBITDA - continuing operations	\$ 67,059	\$ (2,537,648)	\$ (204,075)	\$ (5,233,323)

Adjusted EBITDA is a non-U.S. GAAP measure. See slide 11.

The logo for Forian, featuring a stylized 'F' followed by a circular icon composed of three concentric, slightly offset lines, and then the word 'RIAN' in a clean, sans-serif font.

FORIAN